Health and Fitness Health and Fitness
Thu, April 18, 2013
[ Thu, Apr 18th 2013 ] - Market Wire
Life Technologies Partners with Ridom and Release .. + Software to Speed and Simplify Bacterial Typing
[ Thu, Apr 18th 2013 ] - Market Wire
NW Bio Announces That Another Brain Cancer Patien .. rials Has Surpassed Ten-Year Cancer-Free Survival
[ Thu, Apr 18th 2013 ] - Market Wire
NW Bio Announces $10 Million Registered Direct Offering
[ Thu, Apr 18th 2013 ] - Market Wire
Team USANA Partners Recognized By Utah Sports Com .. igious Honors at Governor's State of Sport Awards
[ Thu, Apr 18th 2013 ] - Market Wire
Insmed to Present at the 12th Annual Needham Healthcare Conference
[ Thu, Apr 18th 2013 ] - Market Wire
Unilife Develops Unifill Assurea" to Enhance Patient Self-Injection of Biologics
[ Thu, Apr 18th 2013 ] - Market Wire
UMeWorld New Trading Symbol "UMEWF" to Be Effective From April 18, 2013
[ Thu, Apr 18th 2013 ] - Market Wire
Implant Sciences Showcases Its Explosive Trace De .. ection Equipment at Counter Terror Expo in London
[ Thu, Apr 18th 2013 ] - Market Wire
Accuray Provides Clarification on Recently Initiated Voluntary Recalls
[ Thu, Apr 18th 2013 ] - Market Wire
BD Anuncia Aprovao FDA 510(k) e Lanamento Comercial do BD UltraSafe PLUSa" Passive Needle Guard
[ Thu, Apr 18th 2013 ] - Market Wire
United Therapeutics Corporation To Announce First .. ts Before Market Open On Thursday, April 25, 2013
[ Thu, Apr 18th 2013 ] - Market Wire
Un estudio publicado en European Radiology apoya el uso de la tomosntesis de mama de Hologic
Wed, April 17, 2013
[ Wed, Apr 17th 2013 ] - Market Wire
Merus Labs International Inc. Receives Notification From NASDAQ
[ Wed, Apr 17th 2013 ] - Market Wire
KaloBios' Targeted Antibacterial KB001-A to be Fe .. Discussion of "New Defenses Against Old Enemies"
[ Wed, Apr 17th 2013 ] - Market Wire
Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
[ Wed, Apr 17th 2013 ] - Market Wire
Solta Medical to Report First Quarter 2013 Results and Host Conference Call on May 1, 2013
[ Wed, Apr 17th 2013 ] - Market Wire
FDA Advisory Committee Recommends Approval of BREO(TM) ELLIPTA(TM) for the Treatment of COPD
[ Wed, Apr 17th 2013 ] - Market Wire
STAAR Surgical Celebrates Over 350,000 Successful .. CLa" Implants at ASCRS Symposium in San Francisco
[ Wed, Apr 17th 2013 ] - Market Wire
NeoGenomics Schedules its Q1 2013 Earnings Release for April 25, 2013
[ Wed, Apr 17th 2013 ] - Market Wire
Nephros Announces Rights Offering and Temporary R .. duction in Exercise Price for March 2011 Warrants
[ Wed, Apr 17th 2013 ] - Market Wire
Critical Alerts For Merck, NetApp, CSX, Theravance, and Uni-Pixel Released By InvestorsObserver
[ Wed, Apr 17th 2013 ] - Market Wire
BIOLASE Enters Into Agreement for Lambda S.p.A. to Pay Royalties
[ Wed, Apr 17th 2013 ] - Market Wire
Randy Hill Appointed to Vasomedical Board of Directors
[ Wed, Apr 17th 2013 ] - Market Wire
U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care
[ Wed, Apr 17th 2013 ] - Market Wire
SafeCode Drug Technologies to Hire Project Manage .. to Market FDA Approved Painless Injection Device
[ Wed, Apr 17th 2013 ] - Market Wire
Nearly 8 Million Healthcare Personnel Come in Contact with Chemotherapy Drugs, According to CDC
[ Wed, Apr 17th 2013 ] - Market Wire
Cantel Medical To Present At Needham 12th Annual Healthcare Conference
[ Wed, Apr 17th 2013 ] - Market Wire
InterMune To Release First Quarter Financial Results On April 24
[ Wed, Apr 17th 2013 ] - Market Wire
Arena Pharma, Celgene, Incyte, Spectrum Pharma, and Geron Under StockCall's Microscope
[ Wed, Apr 17th 2013 ] - Market Wire
Trading in Theravance Common Stock Halted

Trading in Theravance Common Stock Halted


Published on 2013-04-17 04:17:45 - Market Wire
  Print publication without navigation


April 17, 2013 07:05 ET

Trading in Theravance Common Stock Halted

FDA Advisory Committee to Review BREO™ ELLIPTA™ NDA

SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 17, 2013) - Theravance, Inc. (NASDAQ: [ THRX ]) today announced that NASDAQ halted trading of Theravance common stock this morning, April 17, 2013. The Pulmonary-Allergy Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) meets today to discuss the new drug application (NDA) 204275, for fluticasone furoate (FF) and vilanterol (VI) dry powder inhaler (proposed trade name BREO™ ELLIPTA™), sponsored by GlaxoSmithKline plc (GSK), for the long-term maintenance treatment of airflow obstruction and for reducing exacerbations in patients with chronic obstructive pulmonary disease. FF/VI, an investigational once-daily inhaled corticosteroid/long-acting beta2 agonist (LABA) combination treatment, is in development under the LABA collaboration between GSK and Theravance, Inc.

About Theravance

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Theravance's key programs include: RELVAR™ or BREO™ ELLIPTA™ (FF/VI), ANORO™ ELLIPTA™ (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit Theravance's web site at [ www.theravance.com ].

THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc.

RELVAR™ or BREO™ ELLIPTA™ (FF/VI) and ANORO™ ELLIPTA™ (UMEC/VI) are investigational medicines and are not currently approved anywhere in the world. RELVAR™, BREO™, ANORO™ and ELLIPTA™ are trademarks of the GlaxoSmithKline group of companies. The use of these brand names has not yet been approved by any regulatory authority.

(THRX-G)


Contributing Sources